Locations:
November 10, 2023/News Updates

Cleveland Clinic Among First Hospitals to Perform New Renal Denervation Therapy for Uncontrolled Hypertension

Media Downloads

Content is property of Cleveland Clinic and for news media use only.

Newsroom Renal Denervation Therapy

Following approval from the U.S. Food and Drug Administration on Nov. 7, Cleveland Clinic used a first-of-its-kind ultrasound-based renal denervation on a patient. The Paradise system, created by Recor, works to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries. The system delivers two to three doses of 360-degree ultrasound energy through the main renal arteries to the surrounding nerves, reducing overactivity that fuels hypertension. The system is also water-cooled to protect the renal artery wall. Uncontrolled or resistant hypertension is when your blood pressure remains high or unmanaged, despite taking medications. People with hard-to-treat, resistant hypertension have an even higher risk of stroke, kidney disease and heart failure. “We were fortunate to participate in the pivotal trial of this system, which gave us an early understanding of the device. The safety of this outpatient procedure in our experience, and as demonstrated in the trial, is exciting as it opens up a new avenue of treatment for appropriately selected patients with hypertension,” said Amar Krishnaswamy, M.D., Section Head, Interventional Cardiology at Cleveland Clinic. “As physicians, we strive to provide the most advanced and evidence-based treatment for hypertension patients. Renal denervation is another effective tool that we are excited to be able to offer to help patients with difficult to control hypertension. Our expertise in the diagnosis and treatment of hypertension allows us to select the patients that will most benefit from this new technology,” said Luke Laffin, M.D., Co-Director, Center for Blood Pressure Disorders. “Renal denervation can be an effective adjunctive therapy for blood pressure control in selected patients, and we are now able to offer this option as an advancement to currently available conventional therapies,” said George Thomas, M.D., Director, Center for Blood Pressure Disorders. “Our team of nephrologists and cardiologists in the Center for Blood Pressure Disorders will work collaboratively to identify patients most likely to benefit from this procedure to manage hypertension and improve outcomes.” “We know that only a third of people with high blood pressure in the United States have it under control, and it’s great to have a new option to offer patients, when lifestyle modifications and medicine are not working,” said Dr. Aravinda Nanjundappa, interventional cardiologist at Cleveland Clinic, who also performed the first procedure at Cleveland Clinic.

Latest from the Newsroom

Cleveland Clinic's new teaching kitchen and food pantry at the Langston Hughes Community Health & Education Center

Cleveland Clinic Opens Teaching Kitchen and Food Pantry on Cleveland's East Side

VeloSano riders

$20.2 Million Raised for VeloSano, Funding Cancer Research at Cleveland Clinic in 2026

Photo of spine imaging.

Cleveland Clinic Expands Orthopaedic Care in the Mahoning Valley Through Acquisition of Youngstown Orthopaedic Associates Practice

Lobby of new Toronto location

Cleveland Clinic Canada Moves to New Downtown Toronto Location

Artist's rendering of gene therapy for high triglycerides.

Gene Editing Therapy Trial Dramatically Lowers Dangerous Blood Fat Levels

Artist's illustration of gene editing

Cleveland Clinic First-in-Human Trial Shows Gene-Silencing Therapy for High Cholesterol to Be Safe and Effective

Medical illustration of lipoprotein(a) molecule

Cleveland Clinic Trial Shows Novel Lipoprotein(a) Drug Did Not Reduce Major Cardiovascular Events After Nearly 5 Years

Ali Aminian, M.D., performing bariatric surgery.

Cleveland Clinic Study Finds Bariatric Surgery Effective for Substantial Weight Loss After GLP-1 Intolerance or Limited Weight Loss